ClinicalTrials.gg
CompletedNCT03610464Updated Jun 25, 2019Results posted

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

A Phase 4 interventional study of Amphetamine Extended Release Suspension [Dyanavel] in Attention Deficit Hyperactivity Disorder, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 4 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Tris Pharma, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
4 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
676th of 706
5 · median 70
Started
2018
with 36 others
Phase 4
148 of 807
18 open now
Registered
536th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 676th largest by enrollment of the 706 interventional ones that give a count, is one of 37 that started in 2018, is one of 148 in phase 4, and was the 536th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine extended release oral suspension.

Read the detailed description

DYANAVEL® XR is an extended-release oral suspension that contains 2.5 mg/mL amphetamine base (amphetamine extended-release oral suspension; AMPH EROS). Drug-resin complexation is formed with the amphetamine and sodium polystyrene sulfonate, an ion exchange resin. The extended release feature of the product is achieved by coating a portion of the drug/resin complexes with an extended release coating. AMPH EROS contains approximately a 3.2:1 ratio of d-amphetamine compared to l-amphetamine.

The objective of this study was to evaluate the plasma amphetamine concentration/time profile of AMPH EROS in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of AMPH EROS.

These data will guide appropriate dosing in planned safety and efficacy studies with AMPH EROS in a preschool population with attention-deficit/hyperactivity disorder.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
4 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 4 to 5 years at the time of enrollment into this study;
  2. Body weight ≥ 28 lb. at screening visit;
  3. Diagnosed with ADHD by a psychiatrist, psychologist, developmental pediatrician, pediatrician, or an experienced licensed allied health professional approved by the Sponsor by using the criteria and supported by a structured Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL) interview, administered at the Screening Visit (Visit 0);
  4. Provide written (parent/guardian) prior to participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with any active disorder (other than ADHD) with the exception of specific phobias, learning disorders, motor skills disorders, communication disorders,oppositional defiant disorder, elimination disorders, and sleep disorders
  2. History of chronic medical illnesses including seizure disorder (excluding a history of febrile seizures), moderate to severe hypertension, untreated thyroid disease, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy and known family history of sudden death
  3. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment (liver function test results ≥ 2 times the , blood urea nitrogen, or creatinine)
  4. (CS) abnormal or cardiac findings on physical examination (including the presence of a pathologic murmur)
  5. Use of the following medications within 30 days of dosing:

    • MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine, tranylcypromine);
    • Tricyclic Antidepressants (e.g. Desipramine, protriptyline);
  6. Use of the following medications within 3 days of dosing

    • Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid);
    • Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate,methenamine salts);
  7. Use of atomoxetine within 14 days of dosing
  8. Planned use of prohibited drugs or agents from the screening visit through the end of the study. Medications used to support sleep may be acceptable with the written approval of the sponsor or medical monitor
  9. Abnormal CS laboratory test value at screening that, in the opinion of the sponsor or medical monitor, would preclude study participation
  10. Known history of allergy/ to amphetamine or any of the components of AMPH EROS, heparin flush and topical anesthetics
  11. Parent or guardian's inability or unwillingness to follow directions of the Investigator or study research staff
  12. Any uncontrolled medical condition that in the opinion of the Investigator would preclude study participation
  13. History of significant illness requiring hospitalization, or surgery requiring anesthetics within 30 days of dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Study patients (AMPH EROS)

    All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base

    Drug: Amphetamine Extended Release Suspension [Dyanavel]

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma Concentrations of d- and L-amphetamine

    Plasma Concentration of d- and l-amphetamine measured at 0, 1, 3, 4, 6, 8, 10, 12, and 28 hours postdose.

    Time frame: 0-28 hours postdose

07

Results

Posted Jun 25, 2019

Participant flow

Participant flow — Overall Study
MilestoneStudy Patients (AMPH EROS)
Started5
Completed5
Not completed0

Outcome measures

PrimaryPlasma Concentrations of d- and L-amphetamine

Plasma Concentration of d- and l-amphetamine measured at 0, 1, 3, 4, 6, 8, 10, 12, and 28 hours postdose.

Time frame:
0-28 hours postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentrations of d- and L-amphetamine
ng/mLPlasma Concentration of d-AmphetaminePlasma Concentration of l-Amphetamine
0 hours postdose0 ± 00 ± 0
1 hour postdose3.5 ± 3.01.1 ± 0.9
3 hours postdose19.9 ± 2.26.2 ± 0.7
4 hours postdose20.2 ± 2.56.4 ± 0.8
6 hours postdose17.5 ± 3.25.7 ± 1.1
8 hours postdose16.9 ± 2.25.6 ± 0.8
10 hours postdose14.4 ± 3.34.8 ± 1.1
12 hours postdose11.6 ± 3.23.9 ± 1.1
28 hours postdose2.2 ± 0.70.9 ± 0.2

Adverse events

Collected over 48 hours post-dose. Pharmacokinetics study.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study Patients (AMPH EROS)0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Intention to treat

Age, Continuous
Age, Continuous(Years)Study Patients (AMPH EROS)
Mean4 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)Study Patients (AMPH EROS)
Female2
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Study Patients (AMPH EROS)
Hispanic or Latino2
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Study Patients (AMPH EROS)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White2
More than one race0
Unknown or Not Reported0
Body Mass Index
Body Mass Index(kg/m^2)Study Patients (AMPH EROS)
Mean16.2 ± 1.1
08

Study locations

1 site
  • Meridien Research, Inc.
    Maitland, Florida 32751, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in May 2018, 0 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2018
First posted
Aug 1, 2018
StartActual
May 7, 2018
Primary completionActual
May 23, 2018
CompletionActual
May 23, 2018
Results first posted
Jun 25, 2019
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03610464
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
May 7, 2018
Primary completion
May 23, 2018
Completion
May 23, 2018
Results posted
Jun 25, 2019
Last update
Jun 25, 2019

Study contacts

Antonio Pardo, MD
study director · Tris Pharma, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphetamine

Start the discussion